Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes.

Clin Cancer Res · 2025 · PMC12079100 · PMID 40080442

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A multivariate Cox proportional hazard model analysis of the EAGLE dataset showed a trend toward longer OS for patients with KMT2D mutations treated with durvalumab compared with patients treated with SoC ( Fig. 4F ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.